LYVE1 and liver disorder: The European Association for the study of liver disease published recommendation in 2012 that “immunostaining for GPC3, HSP70, and glutamine synthetase and/or gene expression profiles (GPC3, LYVE1, and survivin) is recommended to differentiate high grade dysplastic nodules from early HCC.